Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics鈥� success hinges on FDA milestones, clinical trial read-outs and shifting reimbursement codes鈥攄etails often buried in dense SEC disclosures. If combing through a 300-page 10-K to find NeuroStar adoption numbers or tracing executive stock sales before trial updates feels overwhelming, you鈥檙e not alone.
StockTitan鈥檚 AI-powered analysis turns that complexity into clarity. Our platform ingests every Neuronetics SEC filing the moment it hits EDGAR and delivers plain-English highlights. Need the latest Neuronetics quarterly earnings report 10-Q filing? We tag revenue from treatment sessions separately from device sales and benchmark margins against prior quarters. Curious about Neuronetics insider trading Form 4 transactions? AG真人官方-time alerts surface each executive sale or purchase, while the AI explains how those moves line up with upcoming FDA decisions.
From the Neuronetics annual report 10-K simplified鈥攚here you鈥檒l find updates on the world鈥檚 largest depression outcomes registry鈥攖o each Neuronetics 8-K material events explained, our coverage is complete. You can even explore the Neuronetics proxy statement executive compensation to see how clinical milestones shape pay packages. Practical use cases include:
- Monitoring Neuronetics Form 4 insider transactions real-time before earnings calls
- Comparing segment growth with AI-generated charts inside every filing
- Flagging new reimbursement language the moment it appears
Whether you鈥檙e understanding Neuronetics SEC documents with AI for the first time or need an expert-level Neuronetics earnings report filing analysis, StockTitan provides the insight鈥攏o medical-device jargon required.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 2,925,554 common shares, with an aggregate market value of $10,883,060.88. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares are to be sold on NASDAQ with an approximate sale date of 08/08/2025.
The notice shows the shares were acquired on 12/10/2024 in connection with a Merger/Acquisition from the issuer and were paid for in cash. The filer reports nothing to report for securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 192,806 common shares with an aggregate market value of $717,238.32. The filing states the sale is expected on or about 08/08/2025 on NASDAQ and lists Morgan Stanley Smith Barney LLC as the broker. The shares were acquired on 12/10/2024 in a merger/acquisition transaction from the issuer and were paid for in cash. The filing reports 66,124,820 shares outstanding and notes Nothing to Report for sales in the past three months.
Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.
The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.
Neuronetics (STIM) Q2-25 10-Q snapshot
Revenue jumped 132% YoY to $38.1 M as the December 2024 Greenbrook acquisition added clinic revenue (61% of sales). Treatment-session revenue grew 32% while NeuroStar device sales fell 13%. Gross margin compressed to 46.6% from 74.0% given the lower-margin clinic mix.
Operating loss improved slightly to $8.1 M, but higher interest cost (SOFR+7%) left net loss to shareholders at $10.1 M (-$0.15/sh); share count more than doubled after a February 2025 secondary offering that raised $18.9 M net. Six-month revenue rose 107% to $70.1 M, with a net loss of $22.8 M.
Cash & equivalents fell to $11.0 M (plus $6.5 M restricted) after a $20.5 M operating cash burn YTD. Long-term debt remains $55.5 M under the Perceptive facility, maturing 2029; leverage covenants commence Q1-26. Equity totals $31.5 M.
Management expects available cash and projected sales to fund operations for at least 12 months and anticipates cost synergies from Greenbrook.
Neuronetics, Inc. (STIM) filed an 8-K on 5-Aug-2025 announcing Amendment No. 3 to its July 2024 Credit Agreement with Perceptive Credit Holdings IV.
- Immediate liquidity: the amendment allows the company to draw a $10 million Tranche 2A term loan on the execution date (1-Aug-2025).
- Covenant relief: the minimum cash/liquidity requirement is reduced to $2 million through 30-Sep-2026, giving the company additional flexibility.
- Equity sweetener: Perceptive receives a warrant for 225,000 common shares; exercise terms were not disclosed in the filing.
Items 2.02 and 7.01 merely furnish (not file) the company鈥檚 Q2-25 earnings press release (Ex. 99.1) and an investor presentation (Ex. 99.2); no financial figures are included in this document.
Exhibits disclosed are: 10.1 (Amendment), 99.1 (press release), 99.2 (presentation) and 104 (iXBRL cover).
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
